Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 2192869

Renal osteodystrophy.

J T McCarthy·R Kumar
View original source ↗Export metadata ↓

Abstract

Renal osteodystrophy is a complex disorder which can be divided into five distinct bone histologic subtypes: mild bone disease, hyperparathyroid bone disease, mixed bone disease, osteomalacia, and low-turnover bone disease. Hyperparathyroidism develops in renal failure due to two principal abnormalities: 1,25(OH)2D3 deficiency and hyperphosphatemia. Treatment of these problems is important in order to prevent hyperparathyroidism. Most cases of osteomalacia, mixed bone disease, and low-turnover bone disease are influenced by aluminum status and parathyroid hormone. Aluminum-associated bone disease can be treated with termination of aluminum exposure and/or deferoxamine therapy. Numerous diagnostic pitfalls exist in the evaluation of renal osteodystrophy, and the bone biopsy is extremely important to avoid these problems and plan proper therapy.

Explore related subjects

Bone DiseasesChronic Kidney Disease-Mineral and Bone DisorderHumansKidney DiseasesJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J T McCarthy, R Kumar. 1990. Renal osteodystrophy.. https://pubmed.ncbi.nlm.nih.gov/2192869/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

Broad phenotypic spectrum caused by an identical heterozygous CDMP-1 mutation in three unrelated families.

CDMP-1, a cartilage-specific member of the TGFss superfamily of secreted signaling molecules, plays a key role in chondrogenesis, growth and patterning of the developing vertebrate skeleton. Homozygous CDMP-1 mutations cause Hunter-Thompson and Grebe types of acromesomelic chondrodysplasia and DuPan syndrome in humans, as well as brachypodism in mice, while heterozygous mutations cause brachydactyly type C (BDC). We present clinical and radiographic data from three unrelated families in which 12 members share the same heterozygous CDMP-1 mutation, an insertion (insG206), resulting in a frameshift predicted to cause functional haploinsufficiency. Although eight mutation carriers display BDC, four have normal hands and feet, confirming nonpenetrance of BDC with CDMP-1 mutations. In addition, several carriers have other skeletal abnormalities, including severe bilateral vertical talus (in two), developmental hip dysplasia (in one), and short stature (in two, who are otherwise unaffected). Premature vertebral end-plate disease was observed in four mutation carriers and was associated with spondylolysis and spondylolisthesis in three of these. Axial skeletal involvement has not been previously reported in association with CDMP-1 mutations. This finding is consistent with CDMP-1 expression in human hypertrophic chondrocytes, which are present in the ring epiphyses of vertebral end plates. Phenotypic variation in BDC has previously been attributed either to locus heterogeneity or to the varied functional effects of different CDMP-1 mutations. The remarkable range of phenotypes caused by this identical CDMP-1 mutation in these families emphasizes the crucial role of genetic background, stochastic variation and/or environmental factors in modifying the observed phenotype. Our findings illustrate that nonpenetrance for the typical features of BDC can be appreciable and that atypical skeletal features that have been reported in some patients with BDC (i.e., clubfoot, short stature, spondylolysis) may also result from CDMP-1 mutation.

Bone Diseases↗
PubMed2003

Is HIV sequestered in bone? Possible implications of virological and immunological findings in some HIV-infected patients with bone disease.

To determine the prevalence of CD4 lymphocyte levels less than 350 cells/mm3 accompanying viral loads (VL) less than 500 copies/ml (discordant CD4 lymphocyte levels/VL) in HIV-infected men with bone pathologies, we conducted a review of the records of 3512 men. We found discordant CD4 lymphocyte levels/VL in 26 (36.1%) out of 72 with bone pathologies, and in 704 (20.5%) out of 3440 without bone pathologies (P < 0.01), and concluded that HIV sequestered in bone was a possible explanation.

Bone Diseases↗
PubMed2003

[Bone substitutes].

A large variety of different bone substitutes are available for the treatment of congenital or acquired bone defects as an alternative to bone transplantation. Complications associated with graft harvesting, limited donor resources, and the potential risk of transmission of infectious diseases have led to the development of multiple concepts of new bone substitutes to minimize the wellknown problems. This article intends to give an overview of the products currently available on the market. Inorganic materials such as ceramics from hydroxyapatite and/or tricalcium phosphate, calcium phosphate cements, calcium sulfates and bioglass,organic materials (polymers) and composites, xenografts,and glass ionomer cements are discussed.

Bone Diseases↗